Another CD19-specific ADC currently evaluated in an ongoing phase I study in relapsed/refractory DLBCL is SGN-CD19A (NCT01786135, Additional file 1: Table S7). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.